As the Cytokine space continues to grow, therapeutic developers are using innovative and novel approaches to improve the targeted delivery of cytokine-based drugs as they expand into Immunology & Inflammation as well as Oncology.

Despite being the first class of immunotherapy drugs approved for the treatment of cancer, subsequent clinical failures with cytokines in oncology, including some 1st generation conjugates, have led to skepticism and reduced investment due to insufficient efficacy of single cytokine approaches, systemic toxicity, and challenges in translating preclinical findings to the clinic.

The 6th Cytokine-Based Drug Development Summit brings together the most influential thought leaders from Candel, Deka Biosciences, Regeneron, Sanofi, ModeX, OSE and others to navigate the key challenges in specificity, toxicity, and efficacy. Join them to explore entirely new approaches and therapeutic modalities, including pro-drug, pulsed, targeted, and multi-specific immunomodulation.

 

Testimonial Banner

2025 Cytokine Trailblazers Include:

60435 Full Event Guide
oncosec_medical_inc_logo

“After decades of research into the potential of cytokines to elicit antitumor immune responses, checkpoint inhibition appears to have made room for a new coming of age for cytokine therapy. It’s exciting to see the development of new technologies that can more precisely leverage the power and beauty of cytokine biology in this new era of cancer immunotherapy.” 

Bridget O’Keeffe
Vice President Clinical Development

This meeting brings together leaders in cytokine biology, therapeutic design, and immune oncology to collectively advance the development of targeted and effective cancer drugs. 

Jamie Spangler
Assistant Professor

Johns Hopkins University 

John Hopkins Ini